Evotec SE chart

Last update: 2022-12-30
Key statistics and financials
Revenue per share 3.96
Dividend & YieldN/A£ (N/A)
Beta 1.15
Market capitalization N/A
Operating cash flow 321.74M
ESG Scores unknown

Company description

Evotec SE operates as drug discovery and development partner for the pharmaceutical and biotechnology industry worldwide. The company is developing pharmaceutical products in various therapeutic areas, such as diabetes and complications of diabetes, fibrosis, infectious diseases, CNS diseases, oncology, pain and inflammation, immunology, rare diseases, respiratory diseases, and women's health. It has collaboration agreements with Bayer AG; Lilly; Chinook Therapeutics; Novo Nordisk A/S; Galapagos; Pfizer Inc.; CONBA Pharmaceutical Co., Ltd.; Bristol Myers Squibb Company; Zhejiang JingXin Pharmaceutical Co., Ltd; Kazia Therapeutics; Apeiron Biologics; and Takeda Pharmaceuticals. The company was formerly known as Evotec AG and changed its name to Evotec SE in April 2019. Evotec SE was incorporated in 1993 and is headquartered in Hamburg, Germany.

Sector: - Industry:

Financial data

Financial Statements

Cashflow Statement 2018-12-31 2019-12-31 2020-12-31 2021-12-31
Change To Liabilities 72.42M -16.71M -12.45M 94.42M
Total Cashflows From Investing Activities -39.13M -86.63M -155.09M -243.85M
Net Borrowings -79.34M 209.36M -5.16M -5.89M
Total Cash From Financing Activities -77.76M 211.26M 246.41M 398.43M
Change To Operating Activities -4.8M -30.7M -32.13M -55.87M
Issuance Of Stock 1.58M 1.9M 251.56M 404.32M
Net Income 84.17M 38.16M 6.28M 215.51M
Change In Cash 42.04M 167.98M 145.55M 276.75M
Effect Of Exchange Rate 2.69M 1.13M 9.51M -66k
Total Cash From Operating Activities 156.24M 42.22M 44.72M 122.24M
Depreciation 29.81M 48.8M 54.25M 65.93M
Change To Account Receivables -1.85M -32.48M -4.18M -48.03M
Other Cashflows From Financing Activities
Change To Netincome -31.15M 24.15M 19.29M -158.6M
Capital Expenditures -27.87M -31.32M -99.07M -118.94M

Income Statement 2018-12-31 2019-12-31 2020-12-31 2021-12-31
Research Development 35.62M 58.43M 63.95M 72.2M
Income Before Tax 72M 56.67M 25.84M 236.98M
Net Income 84.17M 38.16M 6.28M 215.51M
Selling General Administrative 57.01M 66.43M 77.2M 105.44M
Gross Profit 112.02M 132.89M 125.74M 151.54M
Ebit 64.23M 74.77M 50.64M 39.81M
Operating Income 64.23M 74.77M 50.64M 39.81M
Interest Expense -2.59M -7.46M -8.46M -9.25M
Income Tax Expense -12.06M 19.36M 19.56M 21.47M
Total Revenue 375.4M 446.44M 500.92M 618.03M
Cost Of Revenue 263.39M 313.55M 375.18M 466.49M
Total Other Income ExpenseNet 7.76M -18.09M -24.8M 197.17M
Net Income From Continuing Ops 84.06M 37.31M 6.28M 215.51M
Net Income Applicable To Common Shares 84.17M 38.16M 6.28M 215.51M

Balance Sheet Statement 2018-12-31 2019-12-31 2020-12-31 2021-12-31
Total Liabilities 347M 703.88M 737.88M 857.48M
Total Stockholder Equity 424M 477.03M 724.46M 1.38B
Other Current Liabilities 81.94M 96M 99.9M 165.85M
Total Assets 771.88M 1.18B 1.46B 2.24B
Common Stock 149.06M 150.9M 163.91M 176.61M
Other Current Assets 11.44M 11.75M 31.85M 20.95M
Retained Earnings -481.01M -441.18M -432.64M -216.42M
Treasury Stock -27.2M -19.56M -37.52M -12.64M
Cash 109.06M 277.03M 422.58M 699.33M
Total Current Liabilities 196.28M 178.96M 208.46M 324.52M
Other Stockholder Equity -27.2M -19.56M -37.52M -12.64M
Property, Plant, and Equipment 89.31M 238M 337.3M 484.6M
Total Current Assets 249.77M 469.53M 658.84M 1.1B
Net Tangible Assets 79.02M 102.89M 379.05M 1.09B
Net Receivables 74.77M 117.84M 122.22M 176.75M
Accounts Payable 31.14M 31.32M 42.55M 72.6M


Insider Transactions

Here are the insider transactions of stock shares related to Evotec SE:

Filer Name Transaction Text Ownership Date Filer Relation Shares
NO DATA

Insider transaction explanations

Insider buying is the legal purchase of shares by a senior executive or director of a company. "Filer Name" corresponds to the name of the stock buyer or seller. "Transaction Text" describes the transaction. "Ownership" gives information about the transaction type. "Date" is the reported transaction date. "Filer Relation" gives the role of the insider in the company. "Shares" is the value of the transaction. You will find the complete description of the General Transaction Codes on the SEC dedicated page


Investment strategy backtesting

These are the result of three automatic investment systems applied to Evotec SE. You will find the performance of an systematic investment system, a momentum strategy, and a buy the dip trading strategy.


Systematic investment results on Evotec SE

Here is the result of two systematic investment strategies applied to Evotec SE. The first strategy automatically buys the first day of the month, and the second strategy buys the fifteenth day of the month.

Systematic investment equity curve on Evotec SE

The following chart shows the equity curve of the two systematic investment strategies applied to Evotec SE:

Evotec SE automated entries

The systematic investment strategy that buys the first day of the month would give a performance of 0% on the backtest period.

Performance at glance

Performance

0 %

Latent gain

0.0 £

Invested capital

0.0 £

Annualized return

0.0 %
Build your Trading System
Automated Trading using Prorealtime ebook

Momentum strategy results on Evotec SE

This is the result of two momentum investment strategies applied to Evotec SE. The first strategy uses a momentum signal calculated on one quarter, and the second uses a momentum signal calculated on two quarters.

Momentum entry openings on Evotec SE

The following chart shows all the entries opened by the momentum investment system on Evotec SE:

Evotec SE momentum entries
  • The first momentum investment strategy would give -6.99% of return on Evotec SE. That represents -17.53£ of latent gain with 250.76£ of employed capital.
  • The second momentum investment strategy would give 0% of return on Evotec SE. That represents 0.0£ of latent gain with 0.0£ of employed capital.
Performance at glance (1Q Momentum)

Performance

-6.99 %

Latent gain

-17.53 £

Invested capital

250.76 £

Annualized return

-0.0 %
Performance at glance (2Q Momentum)

Performance

0 %

Latent gain

0.0 £

Invested capital

0.0 £

Annualized return

-0.0 %

Momentum equity curve on Evotec SE

The following chart shows the equity curve of the two momentum strategies applied to Evotec SE:

Evotec SE momentum equity

Note: the dividends potentially given by Evotec SE are not integrated into the calculation of the equity curve neither the performance of the strategy. The integration of the dividends will be available soon.


Employed capital on Evotec SE

The following chart shows the employed capital evolution of the two momentum strategies on Evotec SE since the beginning:

Evotec SE

Note: the algorithm buys for a maximum of 250$ per entry. If the stock price is greater than 250£, the system buys only one stock per entry. The investment system stops automatically when the financial exposure reaches 10000£.


Buy the dip strategy result on Evotec SE

Buy the dip entry openings on Evotec SE

Evotec SE

The performance achieved by the robo-advisor on Evotec SE is 0%. That represents 0.0$ of latent gain with 0.0£ of employed capital. The following chart shows Evotec SE stock price with all the entries opened by the automated investment system.

Note: The blue line represents the weekly stock price of Evotec SE, and the green triangles represent the entry openings. The artificall robo-advisor needs at least 100 weeks of trading history to work.

Performance at glance

Performance

0 %

Latent gain

0.0 £

Invested capital

0.0 £

Annualized return

-0.0 %

Equity curve of the strategy applied to Evotec SE

The following chart shows the result of the investment strategy applied to Evotec SE:

Evotec SE

Note: the dividends potentially given by Evotec SE are not integrated into the calculation of the equity curve neither the performance of the strategy. The integration of the dividends will be available soon.


Employed capital on Evotec SE

The following chart shows the employed capital evolution since the beginning of the investment strategy on Evotec SE:

Evotec SE

Note: the algorithm buys for a maximum of 250$ per entry. If the stock price is greater than 250$, the system buys only one stock per entry. The investment system stops automatically when the financial exposure reaches 10000$.


Investment strategies comparison on Evotec SE

In this section, I will compare the three previous investment strategies applied to Evotec SE.

Equity curve comparison on Evotec SE

The following chart shows the equity curve of the artificall advisor, the trend folowing and the automatic investment strategies:

Evotec SE investment strategy comparison

Employed capital comparison on Evotec SE

Evotec SE investment comparison

Performance comparison on Evotec SE

Strategy Latent Profit Growth Employed capital CAGR
Automatic investment 0% 0.0£ 0.0£ 0.0%
Momentum 1 quarter -6.99% -17.53£ 250.76£ -174.75%
Momentum 2 quarters 0% 0.0£ 0.0£ -0.0%
Non-directional 0% 0.0£ 0.0£ -0.0%
Annualized return comparison

Automatic investment

0.0 %

Momentum 1Q

-0.0 %

Momentum 2Q

-0.0 %

Non-directional

-0.0 %

Correlated stocks

Here are the most positively and negatively correlated stocks with Evotec SE:

Positive correlations

Most correlated stocks this year


Most correlated stocks last 3 months

Negative correlation

Most negatively correlated stocks this year


Most negatively correlated stocks last 3 months

Note: The algorithm computes the probability of correlation between Evotec SE and the other stocks. There may be false positives or some missing correlated stocks. If the price of Evotec SE does not vary for 36 weeks, the correlation calculation result will be wrong.


Company information

Company name Evotec SE
Country Germany
City Hamburg
Address Essener Bogen 7
Phone 49 40 560 81 0
Website www.evotec.com
FullTime employees 4521
Industry
Sector
Exchange XLON
Ticker 0IRF.XLON
Market www.londonstockexchange.com

Evotec SE ESG Scores

Environment scores

Environment ESG Factors Scores
Environment Score 0
Peer Environment Performance unknown
Environment Percentile unknown
Palm Oil unknown
Nuclear unknown
Fur Leather unknown
GMO unknown
Coal unknown
Pesticides unknown
Animal Testing unknown

Social scores

Social ESG Factors Scores
Social Score 0
Peer Social Performance unknown
Social Percentile unknown
Highest Controversy unknown
Peer Highest Controversy Performance unknown
Adult unknown
Gambling unknown
Alcoholic unknown
Tobacco unknown
Catholic unknown
Controversial Weapons unknown
Small Arms unknown
Military Contract unknown
Peer Count unknown

Related Controversy:


Governance scores

Governance ESG Factors Scores
Governance Score 0
Peer Governance Performance unknown
Governance Percentile unknown

ESG at glance
Total ESG Scores: unknown
Environment Score: 0
Social Score: 0
Governance Score: 0

ESG Performance: unknown

Peer Group: unknown

Peer Esg Score Performance: unknown

Rating Year: unknown

Rating Month: unknown

Max Age: unknown

Percentile: unknown